Named manufacturer of the first domestic vaccine for COVID-19

The vaccine, developed by the “NICAM them.F. Gamalei” was registered by the Ministry of health. The only platform for vaccine production in Russia, in addition to NICAM, will be a pharmaceutical plant, Binnopharm in Zelenograd. Mass production of the vaccine is planned to start by the end of 2020.

“NICAM them.F. Gamalei” one of the first in the world completed a preclinical study of experimental prototype vaccines against coronavirus. Results of clinical studies confirmed the efficacy and safety of the drug.

According to President AFK “System” Vladimir Chirkov, power plant, Binnopharm allow currently producing about 1.5 million doses of vaccine per year. In the future it is planned to equip the plant with additional equipment that will allow to increase production of the vaccine.

Plant Binnopharm in Zelenograd (part of the Group of companies “in Durban”) is a biopharmaceutical complete cycle complex area of 32 thousand sq m. All technological processes and infrastructure meet national and international standards of GMP. In the area of vaccines, the flagship product of the plant Binnopharm is Regvac In the vaccine against hepatitis B, which is our own design.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]